January 16, 2013
A Hemispherx Biopharma Inc. shareholder hit the drugmaker and its executives with a derivative suit in Pennsylvania federal court Tuesday, accusing the company of lying about the safety and efficacy of its chronic fatigue syndrome drug, which annihilated its stock price after the medication's study results were questioned.